homepage-top-section

Pfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash. The

Pfizer has submitted an application to the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) of its investigational oral antiviral drug, Paxlovid (PF-07321332; ritonavir). Paxlovid

Health Canada has authorised the booster shot of Moderna’s Covid-19 vaccine, Spikevax, for individuals aged 18 years and above. The 50µg booster shot will be given at least

The European Commission (EC) has granted marketing authorisation for Roche’s Ronapreve to treat non-hospitalised Covid-19 patients aged 12 years and above. Ronapreve is a combination of monoclonal antibodies,

Eli Lilly and Company and Boehringer Ingelheim’s Jardiance (empagliflozin) has obtained priority review from the US Food and Drug Administration (FDA) to treat adults with heart failure regardless

French company Valneva has received European Commission (EC) approval for an agreement to supply the company’s inactivated Covid-19 vaccine candidate, VLA2001. Under the terms of the deal, the

Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314. The new gene

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s dapagliflozin as a treatment for people with chronic kidney disease (CKD). It has been recommended

Novavax has completed the rolling submission to the World Health Organization (WHO) for emergency use listing (EUL) of its Covid-19 vaccine candidate, NVX-CoV2373. The company has submitted all